

## HR 4400

Advancing Education on Biosimilars Act of 2019

**Congress:** 116 (2019–2021, Ended)

**Chamber:** House

**Policy Area:** Health

**Introduced:** Sep 19, 2019

**Current Status:** Referred to the Subcommittee on Health.

**Latest Action:** Referred to the Subcommittee on Health. (Sep 20, 2019)

**Official Text:** <https://www.congress.gov/bill/116th-congress/house-bill/4400>

### Sponsor

**Name:** Rep. Bucshon, Larry [R-IN-8]

**Party:** Republican • **State:** IN • **Chamber:** House

### Cosponsors (1 total)

Cosponsor	Party / State	Role	Date Joined
Rep. Engel, Eliot L. [D-NY-16]	D · NY		Sep 19, 2019

### Committee Activity

Committee	Chamber	Activity	Date
Energy and Commerce Committee	House	Referred to	Sep 20, 2019
Ways and Means Committee	House	Referred to	Sep 19, 2019

### Subjects & Policy Tags

**Policy Area:**

Health

### Related Bills

Bill	Relationship	Last Action
116 S 4796	Related bill	<b>Oct 5, 2020:</b> Read twice and referred to the Committee on Finance.
116 HR 8527	Related bill	<b>Oct 2, 2020:</b> Referred to the Committee on Energy and Commerce, and in addition to the Committees on Ways and Means, Education and Labor, the Judiciary, Oversight and Reform, House Administration, Rules, the Budget, and Armed Services, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
116 HR 19	Related bill	<b>Dec 19, 2019:</b> Referred to the Subcommittee on Antitrust, Commercial, and Administrative Law.
116 S 1895	Related bill	<b>Jul 8, 2019:</b> Placed on Senate Legislative Calendar under General Orders. Calendar No. 133.

## **Advancing Education on Biosimilars Act of 2019**

This bill requires the Department of Health and Human Services (HHS) to maintain a website and undertake other activities to educate health care providers, patients, and caregivers about biological products, biosimilar biological products, and interchangeable biosimilar biological products.

Among other activities, HHS must develop or improve continuing education programs that address clinical considerations for biological and related products. Health care providers eligible for the Merit-based Incentive Payment System in Medicare may count completion of such a program as a clinical practice improvement activity.

### **Actions Timeline**

---

- **Sep 20, 2019:** Referred to the Subcommittee on Health.
- **Sep 19, 2019:** Introduced in House
- **Sep 19, 2019:** Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
- **Sep 19, 2019:** Referred to the Subcommittee on Health.